MARKET

CGEN

CGEN

Compugen
NASDAQ
1.990
-0.040
-1.97%
Pre Market: 2.020 +0.03 +1.51% 08:29 06/18 EDT
OPEN
2.010
PREV CLOSE
2.030
HIGH
2.068
LOW
1.980
VOLUME
6.73K
TURNOVER
0
52 WEEK HIGH
3.235
52 WEEK LOW
1.295
MARKET CAP
188.16M
P/E (TTM)
5.55
1D
5D
1M
3M
1Y
5Y
1D
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
PR Newswire · 6h ago
Weekly Report: what happened at CGEN last week (0608-0612)?
Weekly Report · 3d ago
Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026
Benzinga · 06/11 11:14
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
PR Newswire · 06/08 11:00
Weekly Report: what happened at CGEN last week (0601-0605)?
Weekly Report · 06/08 10:31
H.C. Wainwright Keeps Their Buy Rating on Compugen (CGEN)
TipRanks · 06/04 10:58
Weekly Report: what happened at CGEN last week (0525-0529)?
Weekly Report · 06/01 10:36
Weekly Report: what happened at CGEN last week (0518-0522)?
Weekly Report · 05/25 10:40
More
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Webull offers Compugen Ltd (USA) stock information, including NASDAQ: CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.